Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

on behalf of the REGAIN Study Group

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience